Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2023 07:00 ET | Source: Passage Bio

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory...
May 04, 2023 07:00 ET | Source: Passage Bio

Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
April 21, 2023 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
April 17, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
March 27, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
March 06, 2023 07:00 ET | Source: Passage Bio

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial...
March 01, 2023 07:00 ET | Source: Passage Bio

Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or universityScholarship application deadline is April 1 for the initial...
February 28, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
February 27, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
February 24, 2023 07:00 ET | Source: Passage Bio

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of PBGM01 led to a biological effect in patientsPBGM01 administration resulted...